Published: 14 April 2020
Author(s): Antonio Faraone, Alice Poggi, Chiara Cappugi, Lorenzo Tofani, Eleonora Riccobono, Tommaso Giani, Alberto Fortini
Issue: August 2020
Section: Original article

Carbapenems are last-line beta-lactamic antibiotics used for the treatment of critically ill patients with confirmed or suspected infections involving multidrug-resistant (MDR) bacteria [1]. These drugs retain a potent activity against extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, and are regarded as the antibiotics of choice for the treatment of serious infections caused by these organisms [1,2]. In recent decades, along with the rising incidence of ESBL-producing bacteria, an increase in carbapenem consumption has been registered worldwide, both in high and medium-low income countries [2–5].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.